Prof Egan leads the development of advanced MRI methods to develop MR biomarkers for use in future clinical drug trials in neurodegenerative diseases. His research focuses on the development of neuroimaging biomarkers to enable identification of progressive neurodegeneration and neural dysfunction in the clinical neurosciences. His research team has also developed novel MRI techniques to quantify axonal and myelin pathology in patients with Multiple Sclerosis (MS) and animal models of MS.
He has achieved of a substantive body of published work that has made a significant impact on the neuroimaging and neuroscience fields. He has published over 230 papers in peer reviewed journals: 24 in leading particle physics journals (1990-93) resulting from his PhD and post-doctoral research; 25 papers in medical imaging research related to positron emission tomography (1995-99); and over 180 papers in neuroimaging and neuroscience.